TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Shear wave elastography of the testes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Changes in bone mineral density and bone mineral content
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Teachers' Sense of Efficacy
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Student-Teacher Relationship
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Modified Hammersmith Change From Baseline to 6 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Breastfeeding at 3 months
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Breastfeeding at 6 months
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Self-reported reasons for breast reconstruction decisions
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Safety and tolerability assessed by vital signs and ECG
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Patients With Treatment-emergent Adverse Events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Patients With Potentially Clinically Important Changes in ECG Post-baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of Patients With Potentially Clinically Important Changes in Vital Signs Post-baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic accuracy in detecting brain tumor tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Somatization score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Sleep Quality score
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Resilience score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Safety lab tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tumor burden
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: premature cartridge clotting rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Mean number of new and overall total number of gadolinium-enhancing lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Differences in blood glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of Responders Measured by the Investigator's Live Assessment (ILA) at Maximum Frown
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Responders Measured by the SSA at Maximum Frown
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum concentration (Cmax) of omaveloxolone in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma omaveloxolone concentration-time curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of the vaccine strategy
Endpoint domain: Adverse events/effects
Primary endpoint: Time delay from fluid responsiveness to fluid unresponsiveness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Volume of fluid needed from fluid responsiveness to fluid unresponsiveness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with adverse events (AEs) and serious AEs (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Effectiveness of tablet education
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Emotion Regulation Questionnaire (ERQ)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Reappraisal Inventiveness Test (RIT)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Number of units of red blood cell transfusions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Area Under the Plasma Curve From Time Zero to Last Quantifiable Concentration (AUClast)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the Plasma Concentration-Time Curve From Time Zero extrapolated to Infinite Time (AUCinf)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Heart rate at first ventilatory threshold (bpm)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of the tube in lower pathway
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual Analogue Scale (VAS) change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Human milk outflow change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 6 point self-rated breast engorgement scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 5 point perceived improvement scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: The Breastfeeding Self-Efficacy Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Gait Evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline in CNS Vital Signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: best cut-off value of ΔPVI6-8
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Isoprostanes isomer levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of infection or vasculitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Children's Dietary Diversity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Women's dietary diversity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Children's Minimum Meal Frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: ABR Peak V Latency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Adverse reaction to the N-13 ammonia injection
Endpoint domain: Adverse events/effects
Primary endpoint: Lactulose:rhamnose ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: change of corneal erosion grade
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change of tear break up time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change of Schirmer test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardiovascular risk factors alterations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Area Under the Curve/Dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of index cases shedding SARS-CoV-2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Proportion of household contacts shedding SARS-CoV-2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in hair thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in hair density
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in vaccination status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrence/metastasis rate at 3 and 5 years
Endpoint domain: Mortality/survival
Primary endpoint: Safety as assessed by adverse event monitoring
Endpoint domain: Adverse events/effects
Primary endpoint: Reconstitution of EBV-specific CTL immunity with anti-viral efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Improvement in respiratory parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: St-George respiratory questionnaire (SGRQ)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: safety of autologous transplantation
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Eyes With Study Success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cervical spine segmental intervertebral motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Complete Cell Cycle Arrest at Cycle 1 Day 15 (PIK3CA Wild Type Cohort Only)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Complete Cell Cycle Arrest at Cycle 1 Day 15 (Endocrine Resistant Cohort Only)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of Developing Grades III-IV Acute Graft-vs-host Disease (GVHD)
Endpoint domain: Adverse events/effects
Primary endpoint: Drop-out rates in control and intervention group
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Perceptions of the intervention
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Improvement of hypertrophic scars
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Cumulative number of Gd enhanced (T1 weighted) lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anatomic Success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional Success Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Yield of detecting metastatic prostate cancer tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: creatine kinase-MB increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Subcutaneous Impedance (Units of Ohms)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Pulmonary Artery Pressure (Units of mmHg)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Right Atrial Pressure (Units of mmHg)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: OARSI/OMERACT response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of complications after elective surgery
Endpoint domain: Adverse events/effects
Primary endpoint: Response to Senza SCS therapy for upper limb or neck pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Development of Post-operative Acute Kidney Injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change from lean mass index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: average activation for each functional neuroimaging examination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Diagnostic accuracy of MBF and MPI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: tragus-to-wall distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: fibromyalgia impact scale
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: AUCu after single dose of BAY1817080
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax,u after single dose of BAY1817080
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 24-Hour Urine Output
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in tetanus antibody titer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Patient Reported Pain
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Central Corneal Staining Change From Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Grittiness Change From Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with ALK/ROS1/MET mutations detected
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in reaction times
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in EEG spectral and frequency analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Incidence of respiratory failure after extubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: AUC(0-t) for metformin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC(0-inf) for metformin and glimepiride
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain score trajectory
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in self-reported psychosocial scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Incidence of side-effect measures
Endpoint domain: Adverse events/effects
Primary endpoint: Percent agreement with gold standard test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in SHIM Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Bacterial binding of Pseudomonas Aeruginosa
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Event-free survival time
Endpoint domain: Mortality/survival
Primary endpoint: Change of Symptom and Medication score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of patients with clinically significant pocket hematoma
Endpoint domain: Adverse events/effects
Primary endpoint: Weekly Steady-state Exposure of Bevacizumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: systolic ejection volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of Participants With LDL Lower Than 2.5 mmol/L at Month 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of Participants With Response Achieving Targeted LDL-cholesterol Level at Month 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of Participants With Positive Response on Self-estimated Treatment Compliance at Month 12
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Safety of ScTIL210
Endpoint domain: Adverse events/effects
Primary endpoint: Measurement of nerve stimulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in mean OSDI score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in mean conjunctival hyperemia score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Change in mean corneal/conjunctival staining score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Change in mean fluorescein tear break-up time (FTBUT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Prevention of excessive bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients with histologically positive surgical margins
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of Patients Who Experienced a Dose-limiting Toxicity (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Immediate Recall Memory Deterioration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Score of five-item Brief Symptom Rating Scale (BSRS-5)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: incidence of hyperchloremic metabolic acidosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: percentage of patients with hematological changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: percentage of patients with antibodies against RBCs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Breath prompting successful rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Suppressive Effect of Serum Estradiol to Menopausal Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Proportion of patients maintaining remission of depressive symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and tolerability of IMP
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Androgen Receptor (AR) Related Mutations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change from baseline of Angiogenesis in brain MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change from baseline of general cognitive functions index
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change from baseline of exercise VO2 MAX
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of inpatient hospital days
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Change from Baseline sodium level in 24 hour urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) of APX005M + Nivolumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Objective Response Rate (ORR) by RECIST 1.1 and iRECIST
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change of pain scores on the Visual analogue scale (VAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Initiation of PrEP
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in self-reported physical activity level
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Positive PTSD screens
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Immunoglobin antibody response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in life satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Behavioural Assessment Tool Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mean change of individual AP spine BMD (gm/cm2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fertility knowledge increase
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Human growth hormone levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: number of entry in distress pictures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: saccade duration in distress picture
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: average of the number of entry in comfort picture vs neutral and complicity pictures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: average of the saccade duration in comfort picture vs neutral and complicity pictures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median completion of participants
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change from baseline in well-being
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change from baseline in dietary behaviors
Endpoint domain: Life impact
Endpoint subdomain: Nutrition
Primary endpoint: Change from baseline in exercise behaviors
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: clinical benefit rate cycle 1-3
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clinical benefit rate cycle 4 and more
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative neurologic improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Extent of Hyperalgesia Area Proximal to Surgical Wound
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Mortality rate within 48 hours of hospital admission
Endpoint domain: Mortality/survival
Primary endpoint: Satisfaction assessed by Care of the Dying Evaluation (CODE) questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Satisfaction of healthcare workers with care rendered assessed by a staff survey
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Time to PSA failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline in A1c
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: LV Bi-zone pacing success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Duration of Drug-Free Interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes